Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Michael A. Schwarzschild, M.D., Ph.D.

Title
Institution
Department
Address
Phone
Fax
Profile Picture

Biography
1985
Markey Fellowship award, HMS
1987 - 1988
Ryan Fellowship award, HMS
1994 - 1999
Clinical Investigator Development Award, NIH
1999 - 2002
George C. Cotzias Memorial Fellowship Award, APDA
2001
Fox Foundation inaugural research grant program award Awardee
2002 - 2005
Paul Beeson Faculty Scholar in Aging Research Program awardee, AFAR
2005 - 2006
Dorothy Dillon Eweson Lectureships, AFAR
2006
Partners in Excellence Award (mentoring)
2012 - 2018
Elected Chair, Executive Committee, Parkinson Study Group
2013
Member, Linked Clinical Trials Committee, Cure Parkinson's Trust
2018 - 2024
Elected Chair, Executive Committee, Parkinson Study Group
2017 - 2019
Scientific Advisory Board member, Michael J. Fox Foundation for Parkinson's Research

Overview

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01NS110879 (SCHWARZSCHILD, MICHAEL A) Aug 1, 2019 - May 31, 2024
    NIH
    Urate-LRRK2 interactions in Parkinson's disease
    Role: Principal Investigator
  2. R13NS111953 (SCHWARZSCHILD, MICHAEL A) Apr 1, 2019 - Mar 31, 2022
    NIH
    2019 Parkinson Study Group Symposium and Training
    Role: Principal Investigator
  3. U01NS107009 (SCHWARZSCHILD, MICHAEL A) Jul 1, 2018 - Apr 30, 2023
    NIH
    Tele-Health Extension for Phase 3 Parkinson's Disease Trial Cohorts
    Role: Principal Investigator
  4. U13NS103523 (SCHWARZSCHILD, MICHAEL A) Jul 1, 2017 - Jun 30, 2018
    NIH
    2017 Parkinson Study Group Symposium and Training
    Role: Principal Investigator
  5. R13NS098746 (SCHWARZSCHILD, MICHAEL A) Aug 1, 2016 - Jul 31, 2017
    NIH
    2016 Parkinson Study Group Symposium and Training
    Role: Principal Investigator

Featured Content

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Simuni T, Fiske B, Merchant K, Coffey CS, Klingner E, Caspell-Garcia C, Lafontant DE, Matthews H, Wyse RK, Brundin P, Simon DK, Schwarzschild M, Weiner D, Adams J, Venuto C, Dawson TM, Baker L, Kostrzebski M, Ward T, Rafaloff G. Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2021 Mar 01; 78(3):312-320. PMID: 33315105.
    Citations: 1     Fields:    
  2. Tanner CM, Cummings SR, Schwarzschild MA, Brown EG, Dorsey ER, Espay AJ, Galifianakis NB, Goldman SM, Litvan I, Luthra N, McFarland NR, Mitchell KT, Standaert DG, Bauer DC, Greenspan SL, Beck JC, Lyles KW. The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism. NPJ Parkinsons Dis. 2021 Mar 01; 7(1):16. PMID: 33649343.
    Citations:    
  3. Schneider RB, Omberg L, Macklin EA, Daeschler M, Bataille L, Anthwal S, Myers TL, Baloga E, Duquette S, Snyder P, Amodeo K, Tarolli CG, Adams JL, Callahan KF, Gottesman J, Kopil CM, Lungu C, Ascherio A, Beck JC, Biglan K, Espay AJ, Tanner C, Oakes D, Shoulson I, Novak D, Kayson E, Ray Dorsey E, Mangravite L, Schwarzschild MA, Simuni T. Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD). Ann Clin Transl Neurol. 2021 02; 8(2):308-320. PMID: 33350601.
    Citations:    Fields:    Translation:Humans
  4. Chen JF, Schwarzschild MA. Do caffeine and more selective adenosine A2A receptor antagonists protect against dopaminergic neurodegeneration in Parkinson's disease? Parkinsonism Relat Disord. 2020 11; 80 Suppl 1:S45-S53. PMID: 33349580.
    Citations:    Fields:    
  5. Andronesi OC, Nicholson K, Jafari-Khouzani K, Bogner W, Wang J, Chan J, Macklin EA, Levine-Weinberg M, Breen C, Schwarzschild MA, Cudkowicz M, Rosen BR, Paganoni S, Ratai EM. Imaging Neurochemistry and Brain Structure Tracks Clinical Decline and Mechanisms of ALS in Patients. Front Neurol. 2020; 11:590573. PMID: 33343494.
    Citations:    
  6. Hung AY, Schwarzschild MA. Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned. Neurotherapeutics. 2020 10; 17(4):1393-1405. PMID: 33205384.
    Citations:    Fields:    
  7. Ma C, Molsberry S, Li Y, Schwarzschild M, Ascherio A, Gao X. Dietary nicotine intake and risk of Parkinson disease: a prospective study. Am J Clin Nutr. 2020 10 01; 112(4):1080-1087. PMID: 32725131.
    Citations:    Fields:    Translation:HumansPHPublic Health
  8. Crotty GF, Lo RY, Schwarzschild MA. If LRRK2 Set the Fire, Can Nonsteroidal Anti-inflammatory Drugs Wet the Flames? Mov Disord. 2020 10; 35(10):1727-1730. PMID: 33068466.
    Citations: 1     Fields:    Translation:Humans
  9. Crotty GF, Maciuca R, Macklin EA, Wang J, Montalban M, Davis SS, Alkabsh JI, Bakshi R, Chen X, Ascherio A, Astarita G, Huntwork-Rodriguez S, Schwarzschild MA. Association of caffeine and related analytes with resistance to Parkinson disease among LRRK2 mutation carriers: A metabolomic study. Neurology. 2020 12 15; 95(24):e3428-e3437. PMID: 32999056.
    Citations: 2     Fields:    Translation:Humans
  10. Bjornevik K, O'Reilly ÉJ, Cortese M, Furtado JD, Kolonel LN, Le Marchand L, Mccullough ML, Paganoni S, Schwarzschild MA, Shadyab AH, Manson JE, Ascherio A. Pre-diagnostic plasma lipid levels and the risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2021 Feb; 22(1-2):133-143. PMID: 32985910.
    Citations: 1     Fields:    
  11. Molsberry S, Bjornevik K, Hughes KC, Healy B, Schwarzschild M, Ascherio A. Diet pattern and prodromal features of Parkinson disease. Neurology. 2020 10 13; 95(15):e2095-e2108. PMID: 32817391.
    Citations:    Fields:    Translation:Humans
  12. Crotty GF, Schwarzschild MA. Chasing Protection in Parkinson's Disease: Does Exercise Reduce Risk and Progression? Front Aging Neurosci. 2020; 12:186. PMID: 32636740.
    Citations: 1     
  13. Huh YE, Chiang MSR, Locascio JJ, Liao Z, Liu G, Choudhury K, Kuras YI, Tuncali I, Videnovic A, Hunt AL, Schwarzschild MA, Hung AY, Herrington TM, Hayes MT, Hyman BT, Wills AM, Gomperts SN, Growdon JH, Sardi SP, Scherzer CR. ß-Glucocerebrosidase activity in GBA-linked Parkinson disease: The type of mutation matters. Neurology. 2020 08 11; 95(6):e685-e696. PMID: 32540937.
    Citations:    Fields:    Translation:Humans
  14. Espay AJ, Kalia LV, Gan-Or Z, Williams-Gray CH, Bedard PL, Rowe SM, Morgante F, Fasano A, Stecher B, Kauffman MA, Farrer MJ, Coffey CS, Schwarzschild MA, Sherer T, Postuma RB, Strafella AP, Singleton AB, Barker RA, Kieburtz K, Olanow CW, Lozano A, Kordower JH, Cedarbaum JM, Brundin P, Standaert DG, Lang AE. Disease modification and biomarker development in Parkinson disease: Revision or reconstruction? Neurology. 2020 03 17; 94(11):481-494. PMID: 32102975.
    Citations: 10     Fields:    Translation:Humans
  15. Alcalay RN, Kehoe C, Shorr E, Battista R, Hall A, Simuni T, Marder K, Wills AM, Naito A, Beck JC, Schwarzschild MA, Nance M. Correction: Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists. Genet Med. 2020 Feb; 22(2):448. PMID: 31772350.
    Citations:    Fields:    
  16. Palacios N, O'Reilly ÉJ, Schwarzschild MA, Ascherio A. Long-Term Use of Antibiotics and Risk of Parkinson's Disease in the Nurses' Health Study. Parkinsons Dis. 2020; 2020:4038375. PMID: 32399169.
    Citations: 1     
  17. Bjornevik K, Schwarzschild MA, Ascherio A. Big health data and Parkinson's disease epidemiology: Challenges and opportunities. Parkinsonism Relat Disord. 2020 02; 71:58-59. PMID: 31948788.
    Citations:    Fields:    Translation:Humans
  18. Bakshi R, Macklin EA, Hung AY, Hayes MT, Hyman BT, Wills AM, Gomperts SN, Growdon JH, Ascherio A, Scherzer CR, Schwarzschild MA. Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson's Disease in the Harvard Biomarkers Study. J Parkinsons Dis. 2020; 10(2):505-510. PMID: 32250320.
    Citations: 5     Fields:    
  19. Molsberry S, Bjornevik K, Hughes KC, Zhang ZJ, Jeanfavre S, Clish C, Healy B, Schwarzschild M, Ascherio A. Plasma Metabolomic Markers of Insulin Resistance and Diabetes and Rate of Incident Parkinson's Disease. J Parkinsons Dis. 2020; 10(3):1011-1021. PMID: 32250318.
    Citations: 1     Fields:    
  20. Hasimoglu YG, Chen X, Bakshi R, Schwarzschild MA, Macklin EA. Does Serum Urate Change as Parkinson's Disease Progresses? J Parkinsons Dis. 2020; 10(4):1571-1576. PMID: 32773396.
    Citations:    Fields:    
  21. Schootemeijer S, van der Kolk NM, Ellis T, Mirelman A, Nieuwboer A, Nieuwhof F, Schwarzschild MA, de Vries NM, Bloem BR. Barriers and Motivators to Engage in Exercise for Persons with Parkinson's Disease. J Parkinsons Dis. 2020; 10(4):1293-1299. PMID: 32925106.
    Citations:    Fields:    
  22. Shen Y, Li J, Schwarzschild M, Pavlova M, He S, Ascherio A, Wu S, Cui L, Gao X. Plasma urate concentrations and possible REM sleep behavior disorder. Ann Clin Transl Neurol. 2019 12; 6(12):2368-2376. PMID: 31714690.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  23. Hughes KC, Gao X, Molsberry S, Valeri L, Schwarzschild MA, Ascherio A. Physical activity and prodromal features of Parkinson disease. Neurology. 2019 12 03; 93(23):e2157-e2169. PMID: 31719136.
    Citations: 4     Fields:    Translation:Humans
  24. Alcalay RN, Kehoe C, Shorr E, Battista R, Hall A, Simuni T, Marder K, Wills AM, Naito A, Beck JC, Schwarzschild MA, Nance M. Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists. Genet Med. 2020 03; 22(3):574-580. PMID: 31680121.
    Citations:    Fields:    Translation:Humans
  25. Schwarzschild MA, Macklin EA, Bakshi R, Battacharyya S, Logan R, Espay AJ, Hung AY, Bwala G, Goetz CG, Russell DS, Goudreau JL, Parashos SA, Saint-Hilaire MH, Rudolph A, Hare JM, Curhan GC, Ascherio A. Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial. Neurology. 2019 10 01; 93(14):e1328-e1338. PMID: 31484712.
    Citations: 6     Fields:    Translation:Humans
  26. Bakshi R, Macklin EA, Schwarzschild MA. Reply to "Mitochondrial DNA deletions discriminate affected from unaffected LRRK2 mutation carriers". Ann Neurol. 2019 08; 86(2):326-327. PMID: 31148194.
    Citations:    Fields:    Translation:Humans
  27. Bjornevik K, Zhang Z, O'Reilly ÉJ, Berry JD, Clish CB, Deik A, Jeanfavre S, Kato I, Kelly RS, Kolonel LN, Liang L, Marchand LL, McCullough ML, Paganoni S, Pierce KA, Schwarzschild MA, Shadyab AH, Wactawski-Wende J, Wang DD, Wang Y, Manson JE, Ascherio A. Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis. Neurology. 2019 04 30; 92(18):e2089-e2100. PMID: 30926684.
    Citations: 6     Fields:    Translation:Humans
  28. Bakshi R, Macklin EA, Logan R, Zorlu MM, Xia N, Crotty GF, Zhang E, Chen X, Ascherio A, Schwarzschild MA. Higher urate in LRRK2 mutation carriers resistant to Parkinson disease. Ann Neurol. 2019 04; 85(4):593-599. PMID: 30761591.
    Citations: 12     Fields:    Translation:Humans
  29. Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A, Josephs KA, Fasano A, Morgante F, Savica R, Greenamyre JT, Cambi F, Yamasaki TR, Tanner CM, Gan-Or Z, Litvan I, Mata IF, Zabetian CP, Brundin P, Fernandez HH, Standaert DG, Kauffman MA, Schwarzschild MA, Sardi SP, Sherer T, Perry G, Leverenz JB. Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology. 2019 02 12; 92(7):329-337. PMID: 30745444.
    Citations: 29     Fields:    Translation:Humans
  30. Ascherio A, Schwarzschild MA. Lifestyle and Parkinson's disease progression. Mov Disord. 2019 01; 34(1):7-8. PMID: 30653733.
    Citations: 1     Fields:    Translation:Humans
  31. Bjornevik K, O'Reilly ÉJ, Berry JD, Clish CB, Jeanfavre S, Kato I, Kolonel LN, Le Marchand L, McCullough ML, Paganoni S, Schwarzschild MA, Talbott EO, Wallace RB, Zhang Z, Manson JE, Ascherio A. Prediagnostic plasma branched-chain amino acids and the risk of amyotrophic lateral sclerosis. Neurology. 2019 04 30; 92(18):e2081-e2088. PMID: 30429276.
    Citations: 1     Fields:    Translation:Humans
  32. Chen X, Umeh CC, Tainsh RE, Feng DD, Maguire M, Zuo F, Rahimian M, Logan R, Wang X, Ascherio A, Macklin EA, Buys ES, Schwarzschild MA. Dissociation between urate and blood pressure in mice and in people with early Parkinson's disease. EBioMedicine. 2018 Nov; 37:259-268. PMID: 30415890.
    Citations: 2     Fields:    Translation:HumansAnimals
  33. Nicholson K, Chan J, Macklin EA, Levine-Weinberg M, Breen C, Bakshi R, Grasso DL, Wills AM, Jahandideh S, Taylor AA, Beaulieu D, Ennist DL, Andronesi O, Ratai EM, Schwarzschild MA, Cudkowicz M, Paganoni S. Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2018 Dec; 5(12):1522-1533. PMID: 30564619.
    Citations: 3     Fields:    
  34. Bhattacharyya S, Macklin EA, Schwarzschild MA. Cardiovascular Safety of Febuxostat. N Engl J Med. 2018 10 18; 379(16):1582. PMID: 30338966.
    Citations:    Fields:    Translation:Humans
  35. Palacios N, Hughes KC, Cereda E, Schwarzschild MA, Ascherio A. Appendectomy and risk of Parkinson's disease in two large prospective cohorts of men and women. Mov Disord. 2018 09; 33(9):1492-1496. PMID: 30218460.
    Citations: 9     Fields:    Translation:Humans
  36. Iwaki H, Hughes KC, Gao X, Schwarzschild MA, Ascherio A. The association between restless legs syndrome and premotor symptoms of Parkinson's disease. J Neurol Sci. 2018 11 15; 394:41-44. PMID: 30212740.
    Citations: 3     Fields:    Translation:Humans
  37. Hughes KC, Gao X, Baker JM, Stephen C, Kim IY, Valeri L, Schwarzschild MA, Ascherio A. Non-motor features of Parkinson's disease in a nested case-control study of US men. J Neurol Neurosurg Psychiatry. 2018 12; 89(12):1288-1295. PMID: 30076266.
    Citations: 6     Fields:    Translation:Humans
  38. Bakshi R, Xu Y, Mueller KA, Chen X, Granucci E, Paganoni S, Sadri-Vakili G, Schwarzschild MA. Urate mitigates oxidative stress and motor neuron toxicity of astrocytes derived from ALS-linked SOD1G93A mutant mice. Mol Cell Neurosci. 2018 10; 92:12-16. PMID: 29928993.
    Citations: 5     Fields:    Translation:AnimalsCells
  39. Hughes KC, Gao X, O'Reilly EJ, Kim IY, Wang M, Weisskopf MG, Schwarzschild MA, Ascherio A. Genetic variants related to urate and risk of Parkinson's disease. Parkinsonism Relat Disord. 2018 08; 53:4-9. PMID: 29789205.
    Citations: 2     Fields:    Translation:Humans
  40. Kim IY, O'Reilly ÉJ, Hughes KC, Gao X, Schwarzschild MA, Hannan MT, Betensky RA, Ascherio A. Integration of risk factors for Parkinson disease in 2 large longitudinal cohorts. Neurology. 2018 05 08; 90(19):e1646-e1653. PMID: 29643081.
    Citations: 5     Fields:    Translation:Humans
  41. Cai W, Feng D, Schwarzschild MA, McLean PJ, Chen X. Bimolecular Fluorescence Complementation of Alpha-synuclein Demonstrates its Oligomerization with Dopaminergic Phenotype in Mice. EBioMedicine. 2018 Mar; 29:13-22. PMID: 29433982.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  42. Kim IY, O'Reilly ÉJ, Hughes KC, Gao X, Schwarzschild MA, McCullough ML, Hannan MT, Betensky RA, Ascherio A. Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk. Mov Disord. 2018 03; 33(3):414-420. PMID: 29318639.
    Citations: 5     Fields:    Translation:Humans
  43. O'Reilly ÉJ, Bjornevik K, Schwarzschild MA, McCullough ML, Kolonel LN, Le Marchand L, Manson JE, Ascherio A. Pre-diagnostic plasma urate and the risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018 05; 19(3-4):194-200. PMID: 29277115.
    Citations: 3     Fields:    Translation:Humans
  44. Ascherio A, Schwarzschild MA. Dietary antioxidants and Parkinson's disease. Mov Disord. 2017 11; 32(11):1501-1503. PMID: 28976040.
    Citations:    Fields:    Translation:Humans
  45. Palacios N, Fitzgerald KC, Hart JE, Weisskopf M, Schwarzschild MA, Ascherio A, Laden F. Air Pollution and Risk of Parkinson's Disease in a Large Prospective Study of Men. Environ Health Perspect. 2017 08 18; 125(8):087011. PMID: 28886605.
    Citations: 5     Fields:    Translation:HumansPHPublic Health
  46. Crotty GF, Ascherio A, Schwarzschild MA. Targeting urate to reduce oxidative stress in Parkinson disease. Exp Neurol. 2017 12; 298(Pt B):210-224. PMID: 28622913.
    Citations: 21     Fields:    Translation:HumansAnimals
  47. Hughes KC, Gao X, Kim IY, Wang M, Weisskopf MG, Schwarzschild MA, Ascherio A. Intake of dairy foods and risk of Parkinson disease. Neurology. 2017 Jul 04; 89(1):46-52. PMID: 28596209.
    Citations: 15     Fields:    Translation:Humans
  48. Quinti L, Dayalan Naidu S, Träger U, Chen X, Kegel-Gleason K, Llères D, Connolly C, Chopra V, Low C, Moniot S, Sapp E, Tousley AR, Vodicka P, Van Kanegan MJ, Kaltenbach LS, Crawford LA, Fuszard M, Higgins M, Miller JRC, Farmer RE, Potluri V, Samajdar S, Meisel L, Zhang N, Snyder A, Stein R, Hersch SM, Ellerby LM, Weerapana E, Schwarzschild MA, Steegborn C, Leavitt BR, Degterev A, Tabrizi SJ, Lo DC, DiFiglia M, Thompson LM, Dinkova-Kostova AT, Kazantsev AG. KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients. Proc Natl Acad Sci U S A. 2017 06 06; 114(23):E4676-E4685. PMID: 28533375.
    Citations: 23     Fields:    Translation:HumansAnimalsCells
  49. Chen X, Feng D, Schwarzschild MA, Gao X. Red hair, MC1R variants, and risk for Parkinson's disease - a meta-analysis. Ann Clin Transl Neurol. 2017 03; 4(3):212-216. PMID: 28275654.
    Citations: 4     Fields:    
  50. Espay AJ, Schwarzschild MA, Tanner CM, Fernandez HH, Simon DK, Leverenz JB, Merola A, Chen-Plotkin A, Brundin P, Kauffman MA, Erro R, Kieburtz K, Woo D, Macklin EA, Standaert DG, Lang AE. Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. Mov Disord. 2017 03; 32(3):319-324. PMID: 28233927.
    Citations: 27     Fields:    Translation:Humans
  51. Chen X, Chen H, Cai W, Maguire M, Ya B, Zuo F, Logan R, Li H, Robinson K, Vanderburg CR, Yu Y, Wang Y, Fisher DE, Schwarzschild MA. The melanoma-linked "redhead" MC1R influences dopaminergic neuron survival. Ann Neurol. 2017 Mar; 81(3):395-406. PMID: 28019657.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  52. Schwarzschild MA. Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects? J Parkinsons Dis. 2017; 7(1):79-80. PMID: 28035939.
    Citations: 2     Fields:    
  53. Paganoni S, Schwarzschild MA. Urate as a Marker of Risk and Progression of Neurodegenerative Disease. Neurotherapeutics. 2017 01; 14(1):148-153. PMID: 27995438.
    Citations: 23     Fields:    Translation:HumansAnimals
  54. Kim IY, O'Reilly ÉJ, Hughes KC, Gao X, Schwarzschild MA, Ascherio A. Differences in Parkinson's Disease Risk with Caffeine Intake and Postmenopausal Hormone Use. J Parkinsons Dis. 2017; 7(4):677-684. PMID: 28984617.
    Citations: 1     Fields:    Translation:Humans
  55. Hughes KC, Gao X, Kim IY, Rimm EB, Wang M, Weisskopf MG, Schwarzschild MA, Ascherio A. Intake of antioxidant vitamins and risk of Parkinson's disease. Mov Disord. 2016 12; 31(12):1909-1914. PMID: 27787934.
    Citations: 18     Fields:    Translation:Humans
  56. Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention. Lancet Neurol. 2016 Nov; 15(12):1257-1272. PMID: 27751556.
    Citations: 230     Fields:    Translation:Humans
  57. O'Reilly ÉJ, Liu D, Johns DR, Cudkowicz ME, Paganoni S, Schwarzschild MA, Leitner M, Ascherio A. Serum urate at trial entry and ALS progression in EMPOWER. Amyotroph Lateral Scler Frontotemporal Degener. 2017 02; 18(1-2):120-125. PMID: 27677562.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  58. Jackson EK, Boison D, Schwarzschild MA, Kochanek PM. Purines: forgotten mediators in traumatic brain injury. J Neurochem. 2016 Apr; 137(2):142-53. PMID: 26809224.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  59. Xu K, Di Luca DG, Orrú M, Xu Y, Chen JF, Schwarzschild MA. Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors. Neuroscience. 2016 May 13; 322:129-37. PMID: 26905951.
    Citations: 22     Fields:    Translation:AnimalsCells
  60. Bhattacharyya S, Bakshi R, Logan R, Ascherio A, Macklin EA, Schwarzschild MA. Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease. Mov Disord. 2016 Mar; 31(3):417-21. PMID: 26805433.
    Citations: 6     Fields:    Translation:Humans
  61. Gao X, O'Reilly ÉJ, Schwarzschild MA, Ascherio A. Prospective study of plasma urate and risk of Parkinson disease in men and women. Neurology. 2016 Feb 09; 86(6):520-6. PMID: 26764029.
    Citations: 39     Fields:    Translation:Humans
  62. Bakshi R, Zhang H, Logan R, Joshi I, Xu Y, Chen X, Schwarzschild MA. Neuroprotective effects of urate are mediated by augmenting astrocytic glutathione synthesis and release. Neurobiol Dis. 2015 Oct; 82:574-579. PMID: 26341543.
    Citations: 18     Fields:    Translation:AnimalsCells
  63. Locascio JJ, Eberly S, Liao Z, Liu G, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Dhima K, Hung AY, Flaherty AW, Schwarzschild MA, Hayes MT, Wills AM, Shivraj Sohur U, Mejia NI, Selkoe DJ, Oakes D, Shoulson I, Dong X, Marek K, Zheng B, Ivinson A, Hyman BT, Growdon JH, Sudarsky LR, Schlossmacher MG, Ravina B, Scherzer CR. Association between a-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. Brain. 2015 Sep; 138(Pt 9):2659-71. PMID: 26220939.
    Citations: 29     Fields:    Translation:Humans
  64. Chen X, Wales P, Quinti L, Zuo F, Moniot S, Herisson F, Rauf NA, Wang H, Silverman RB, Ayata C, Maxwell MM, Steegborn C, Schwarzschild MA, Outeiro TF, Kazantsev AG. The sirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson's disease but not amyotrophic lateral sclerosis and cerebral ischemia. PLoS One. 2015; 10(1):e0116919. PMID: 25608039.
    Citations: 36     Fields:    Translation:HumansAnimalsCells
  65. Palacios N, Fitzgerald KC, Hart JE, Weisskopf MG, Schwarzschild MA, Ascherio A, Laden F. Particulate matter and risk of Parkinson disease in a large prospective study of women. Environ Health. 2014 Oct 07; 13:80. PMID: 25294559.
    Citations: 14     Fields:    Translation:HumansPHPublic Health
  66. Simon KC, Eberly S, Gao X, Oakes D, Tanner CM, Shoulson I, Fahn S, Schwarzschild MA, Ascherio A. Mendelian randomization of serum urate and parkinson disease progression. Ann Neurol. 2014 Dec; 76(6):862-8. PMID: 25257975.
    Citations: 28     Fields:    Translation:Humans
  67. Schwarzschild MA, Macklin EA, Ascherio A. Urate and neuroprotection trials. Lancet Neurol. 2014 Aug; 13(8):758. PMID: 25030508.
    Citations: 8     Fields:    Translation:Humans
  68. Palacios N, Fitzgerald K, Roberts AL, Hart JE, Weisskopf MG, Schwarzschild MA, Ascherio A, Laden F. A prospective analysis of airborne metal exposures and risk of Parkinson disease in the nurses' health study cohort. Environ Health Perspect. 2014 Sep; 122(9):933-8. PMID: 24905870.
    Citations: 17     Fields:    Translation:HumansPHPublic Health
  69. Cipriani S, Bakshi R, Schwarzschild MA. Protection by inosine in a cellular model of Parkinson's disease. Neuroscience. 2014 Aug 22; 274:242-9. PMID: 24880154.
    Citations: 6     Fields:    Translation:AnimalsCells
  70. Kachroo A, Schwarzschild MA. Allopurinol reduces levels of urate and dopamine but not dopaminergic neurons in a dual pesticide model of Parkinson's disease. Brain Res. 2014 May 14; 1563:103-9. PMID: 24680743.
    Citations: 4     Fields:    Translation:AnimalsCells
  71. Wong JC, Li Y, Schwarzschild MA, Ascherio A, Gao X. Restless legs syndrome: an early clinical feature of Parkinson disease in men. Sleep. 2014 Feb 01; 37(2):369-72. PMID: 24497665.
    Citations: 21     Fields:    Translation:Humans
  72. Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, Gartner M, Hung A, Bwala G, Lenehan R, Encarnacion E, Ainslie M, Castillo R, Togasaki D, Barles G, Friedman JH, Niles L, Carter JH, Murray M, Goetz CG, Jaglin J, Ahmed A, Russell DS, Cotto C, Goudreau JL, Russell D, Parashos SA, Ede P, Saint-Hilaire MH, Thomas CA, James R, Stacy MA, Johnson J, Gauger L, Antonelle de Marcaida J, Thurlow S, Isaacson SH, Carvajal L, Rao J, Cook M, Hope-Porche C, McClurg L, Grasso DL, Logan R, Orme C, Ross T, Brocht AF, Constantinescu R, Sharma S, Venuto C, Weber J, Eaton K. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014 Feb; 71(2):141-50. PMID: 24366103.
    Citations: 71     Fields:    Translation:Humans
  73. McFarland NR, Dimant H, Kibuuka L, Ebrahimi-Fakhari D, Desjardins CA, Danzer KM, Danzer M, Fan Z, Schwarzschild MA, Hirst W, McLean PJ. Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not a-synuclein-induced neuronal cell loss. PLoS One. 2014; 9(1):e86048. PMID: 24465863.
    Citations: 13     Fields:    Translation:HumansAnimals
  74. Hung AY, Schwarzschild MA. Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline? Neurotherapeutics. 2014 Jan; 11(1):34-46. PMID: 24310604.
    Citations: 7     Fields:    Translation:HumansAnimals
  75. Ding H, Dhima K, Lockhart KC, Locascio JJ, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Hayes MT, Sohur US, Wills AM, Mollenhauer B, Flaherty AW, Hung AY, Mejia N, Khurana V, Gomperts SN, Selkoe DJ, Schwarzschild MA, Schlossmacher MG, Hyman BT, Sudarsky LR, Growdon JH, Scherzer CR. Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology. 2013 Oct 22; 81(17):1531-7. PMID: 24068787.
    Citations: 36     Fields:    Translation:Humans
  76. McFarland NR, Burdett T, Desjardins CA, Frosch MP, Schwarzschild MA. Postmortem brain levels of urate and precursors in Parkinson's disease and related disorders. Neurodegener Dis. 2013; 12(4):189-98. PMID: 23467193.
    Citations: 14     Fields:    Translation:HumansCells
  77. Wills AM, Eberly S, Tennis M, Lang AE, Messing S, Togasaki D, Tanner CM, Kamp C, Chen JF, Oakes D, McDermott MP, Schwarzschild MA. Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord. 2013 Mar; 28(3):380-3. PMID: 23339054.
    Citations: 15     Fields:    Translation:Humans
  78. Brundin P, Barker RA, Conn PJ, Dawson TM, Kieburtz K, Lees AJ, Schwarzschild MA, Tanner CM, Isaacs T, Duffen J, Matthews H, Wyse RK. Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments. J Parkinsons Dis. 2013 Jan 01; 3(3):231-9. PMID: 24018336.
    Citations: 17     Fields:    Translation:Humans
  79. Chen X, Burdett TC, Desjardins CA, Logan R, Cipriani S, Xu Y, Schwarzschild MA. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc Natl Acad Sci U S A. 2013 Jan 02; 110(1):300-5. PMID: 23248282.
    Citations: 43     Fields:    Translation:AnimalsCells
  80. Gao X, Simon KC, Schwarzschild MA, Ascherio A. Age, statin use, and the risk for incident Parkinson disease-reply. Arch Neurol. 2012 Oct 1; 69(10):1381. PMID: 23044597.
    Citations:    
  81. Gao X, Simon KC, Schwarzschild MA, Ascherio A. Age, statin use, and the risk for incident Parkinson disease-reply. Arch Neurol. 2012 Oct 01; 69(10):1381. PMID: 23754004.
    Citations:    Fields:    
  82. Ravina B, Marek K, Eberly S, Oakes D, Kurlan R, Ascherio A, Beal F, Beck J, Flagg E, Galpern WR, Harman J, Lang AE, Schwarzschild M, Tanner C, Shoulson I. Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord. 2012 Sep 15; 27(11):1392-7. PMID: 22976926.
    Citations: 33     Fields:    Translation:Humans
  83. Salamone JD, Collins-Praino LE, Pardo M, Podurgiel SJ, Baqi Y, Müller CE, Schwarzschild MA, Correa M. Conditional neural knockout of the adenosine A(2A) receptor and pharmacological A(2A) antagonism reduce pilocarpine-induced tremulous jaw movements: studies with a mouse model of parkinsonian tremor. Eur Neuropsychopharmacol. 2013 Aug; 23(8):972-7. PMID: 22947264.
    Citations: 8     Fields:    Translation:AnimalsCells
  84. Palacios N, Gao X, McCullough ML, Schwarzschild MA, Shah R, Gapstur S, Ascherio A. Caffeine and risk of Parkinson's disease in a large cohort of men and women. Mov Disord. 2012 Sep 01; 27(10):1276-82. PMID: 22927157.
    Citations: 53     Fields:    Translation:Humans
  85. Cipriani S, Desjardins CA, Burdett TC, Xu Y, Xu K, Schwarzschild MA. Protection of dopaminergic cells by urate requires its accumulation in astrocytes. J Neurochem. 2012 Oct; 123(1):172-81. PMID: 22671773.
    Citations: 18     Fields:    Translation:AnimalsCells
  86. Chen X, Wu G, Schwarzschild MA. Urate in Parkinson's disease: more than a biomarker? Curr Neurol Neurosci Rep. 2012 Aug; 12(4):367-75. PMID: 22580741.
    Citations: 24     Fields:    Translation:HumansAnimals
  87. Schwarzschild MA. Caffeine in Parkinson disease: better for cruise control than snooze patrol? Neurology. 2012 Aug 14; 79(7):616-8. PMID: 22855870.
    Citations: 4     Fields:    Translation:Humans
  88. Palacios N, Gao X, O'Reilly E, Schwarzschild M, McCullough ML, Mayo T, Gapstur SM, Ascherio AA. Alcohol and risk of Parkinson's disease in a large, prospective cohort of men and women. Mov Disord. 2012 Jul; 27(8):980-7. PMID: 22714720.
    Citations: 20     Fields:    Translation:Humans
  89. Burdett TC, Desjardins CA, Logan R, McFarland NR, Chen X, Schwarzschild MA. Efficient determination of purine metabolites in brain tissue and serum by high-performance liquid chromatography with electrochemical and UV detection. Biomed Chromatogr. 2013 Jan; 27(1):122-9. PMID: 22674671.
    Citations: 7     Fields:    Translation:HumansAnimals
  90. Cipriani S, Desjardins CA, Burdett TC, Xu Y, Xu K, Schwarzschild MA. Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease. PLoS One. 2012; 7(5):e37331. PMID: 22606360.
    Citations: 23     Fields:    Translation:AnimalsCells
  91. Gao X, Cassidy A, Schwarzschild MA, Rimm EB, Ascherio A. Habitual intake of dietary flavonoids and risk of Parkinson disease. Neurology. 2012 Apr 10; 78(15):1138-45. PMID: 22491871.
    Citations: 56     Fields:    Translation:HumansAnimals
  92. Gao X, Simon KC, Schwarzschild MA, Ascherio A. Prospective study of statin use and risk of Parkinson disease. Arch Neurol. 2012 Mar; 69(3):380-4. PMID: 22410446.
    Citations: 32     Fields:    Translation:Humans
  93. Matos M, Augusto E, Santos-Rodrigues AD, Schwarzschild MA, Chen JF, Cunha RA, Agostinho P. Adenosine A2A receptors modulate glutamate uptake in cultured astrocytes and gliosomes. Glia. 2012 May; 60(5):702-16. PMID: 22298379.
    Citations: 42     Fields:    Translation:AnimalsCells
  94. Kachroo A, Schwarzschild MA. Adenosine A2A receptor gene disruption protects in an a-synuclein model of Parkinson's disease. Ann Neurol. 2012 Feb; 71(2):278-82. PMID: 22367999.
    Citations: 26     Fields:    Translation:Animals
  95. Palacios N, Gao X, Schwarzschild M, Ascherio A. Declining quality of life in Parkinson disease before and after diagnosis. J Parkinsons Dis. 2012; 2(2):153-60. PMID: 23939439.
    Citations: 1     Fields:    Translation:Humans
  96. Ding H, Sarokhan AK, Roderick SS, Bakshi R, Maher NE, Ashourian P, Kan CG, Chang S, Santarlasci A, Swords KE, Ravina BM, Hayes MT, Sohur US, Wills AM, Flaherty AW, Unni VK, Hung AY, Selkoe DJ, Schwarzschild MA, Schlossmacher MG, Sudarsky LR, Growdon JH, Ivinson AJ, Hyman BT, Scherzer CR. Association of SNCA with Parkinson: replication in the Harvard NeuroDiscovery Center Biomarker Study. Mov Disord. 2011 Oct; 26(12):2283-6. PMID: 21953863.
    Citations: 13     Fields:    Translation:Humans
  97. Huang X, Auinger P, Eberly S, Oakes D, Schwarzschild M, Ascherio A, Mailman R, Chen H. Serum cholesterol and the progression of Parkinson's disease: results from DATATOP. PLoS One. 2011; 6(8):e22854. PMID: 21853051.
    Citations: 17     Fields:    Translation:Humans
  98. Palacios N, Gao X, McCullough ML, Jacobs EJ, Patel AV, Mayo T, Schwarzschild MA, Ascherio A. Obesity, diabetes, and risk of Parkinson's disease. Mov Disord. 2011 Oct; 26(12):2253-9. PMID: 21739472.
    Citations: 37     Fields:    Translation:Humans
  99. Gao X, Chen H, Schwarzschild MA, Ascherio A. A prospective study of bowel movement frequency and risk of Parkinson's disease. Am J Epidemiol. 2011 Sep 01; 174(5):546-51. PMID: 21719744.
    Citations: 33     Fields:    Translation:Humans
  100. Schwarzschild MA, Marek K, Eberly S, Oakes D, Shoulson I, Jennings D, Seibyl J, Ascherio A. Serum urate and probability of dopaminergic deficit in early "Parkinson's disease". Mov Disord. 2011 Aug 15; 26(10):1864-8. PMID: 21538532.
    Citations: 18     Fields:    Translation:Humans
  101. Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology. 2011 Mar 08; 76(10):863-9. PMID: 21368281.
    Citations: 95     Fields:    Translation:Humans
  102. Barkhoudarian MT, Schwarzschild MA. Preclinical jockeying on the translational track of adenosine A2A receptors. Exp Neurol. 2011 Apr; 228(2):160-4. PMID: 21211537.
    Citations: 5     Fields:    Translation:HumansAnimals
  103. Schwarzschild MA. The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology. 2010 Nov 23; 75(21):1943-4; author reply 1944-5. PMID: 21098412.
    Citations: 1     Fields:    Translation:Humans
  104. Gao X, Schwarzschild MA, O'Reilly EJ, Wang H, Ascherio A. Restless legs syndrome and Parkinson's disease in men. Mov Disord. 2010 Nov 15; 25(15):2654-7. PMID: 20737545.
    Citations: 12     Fields:    Translation:Humans
  105. Cipriani S, Chen X, Schwarzschild MA. Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis. Biomark Med. 2010 Oct; 4(5):701-12. PMID: 20945982.
    Citations: 46     Fields:    Translation:Humans
  106. Black YD, Xiao D, Pellegrino D, Kachroo A, Brownell AL, Schwarzschild MA. Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease. Neurosci Lett. 2010 Dec 17; 486(3):161-5. PMID: 20854878.
    Citations: 8     Fields:    Translation:Animals
  107. Simon KC, Gao X, Chen H, Schwarzschild MA, Ascherio A. Calcium channel blocker use and risk of Parkinson's disease. Mov Disord. 2010 Sep 15; 25(12):1818-22. PMID: 20669249.
    Citations: 15     Fields:    Translation:Humans
  108. Xiao D, Cassin JJ, Healy B, Burdett TC, Chen JF, Fredholm BB, Schwarzschild MA. Deletion of adenosine A1 or A(2A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease. Brain Res. 2011 Jan 07; 1367:310-8. PMID: 20828543.
    Citations: 17     Fields:    Translation:Animals
  109. Gardener H, Gao X, Chen H, Schwarzschild MA, Spiegelman D, Ascherio A. Prenatal and early life factors and risk of Parkinson's disease. Mov Disord. 2010 Aug 15; 25(11):1560-7. PMID: 20740569.
    Citations: 6     Fields:    Translation:Humans
  110. O'Reilly EJ, Gao X, Weisskopf MG, Chen H, Schwarzschild MA, Spiegelman D, Ascherio A. Plasma urate and Parkinson's disease in women. Am J Epidemiol. 2010 Sep 15; 172(6):666-70. PMID: 20682521.
    Citations: 24     Fields:    Translation:Humans
  111. Palacios N, Weisskopf M, Simon K, Gao X, Schwarzschild M, Ascherio A. Polymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson's disease in men and women. Parkinsonism Relat Disord. 2010 Jul; 16(6):370-5. PMID: 20304699.
    Citations: 16     Fields:    Translation:Humans
  112. Kachroo A, Irizarry MC, Schwarzschild MA. Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration. Exp Neurol. 2010 Jun; 223(2):657-61. PMID: 20188092.
    Citations: 28     Fields:    Translation:AnimalsCells
  113. Schwarzschild MA. Rasagiline in Parkinson's disease. N Engl J Med. 2010 Feb 18; 362(7):658; author reply 658-9. PMID: 20187261.
    Citations: 3     Fields:    Translation:Humans
  114. Youdim MB. Rasagiline in Parkinson's disease. N Engl J Med. 2010 Feb 18; 362(7):657-8; author reply 658-9. PMID: 20164492.
    Citations: 5     Fields:    Translation:HumansAnimals
  115. Xu K, Xu YH, Chen JF, Schwarzschild MA. Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease. Neuroscience. 2010 May 05; 167(2):475-81. PMID: 20167258.
    Citations: 27     Fields:    Translation:Animals
  116. Gao X, Schwarzschild MA, O'Reilly EJ, Wang H, Ascherio A. Restless legs syndrome and erectile dysfunction. Sleep. 2010 Jan; 33(1):75-9. PMID: 20120623.
    Citations: 10     Fields:    Translation:Humans
  117. Morelli M, Carta AR, Kachroo A, Schwarzschild MA. Pathophysiological roles for purines: adenosine, caffeine and urate. Prog Brain Res. 2010; 183:183-208. PMID: 20696321.
    Citations: 33     Fields:    Translation:Humans
  118. Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009 Dec; 66(12):1460-8. PMID: 19822770.
    Citations: 116     Fields:    Translation:Humans
  119. Quiroz C, Luján R, Uchigashima M, Simoes AP, Lerner TN, Borycz J, Kachroo A, Canas PM, Orru M, Schwarzschild MA, Rosin DL, Kreitzer AC, Cunha RA, Watanabe M, Ferré S. Key modulatory role of presynaptic adenosine A2A receptors in cortical neurotransmission to the striatal direct pathway. ScientificWorldJournal. 2009 Nov 18; 9:1321-44. PMID: 19936569.
    Citations: 40     Fields:    Translation:AnimalsCells
  120. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Family history of melanoma and Parkinson disease risk. Neurology. 2009 Oct 20; 73(16):1286-91. PMID: 19841380.
    Citations: 40     Fields:    Translation:Humans
  121. Carta AR, Kachroo A, Schintu N, Xu K, Schwarzschild MA, Wardas J, Morelli M. Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neurochem. 2009 Dec; 111(6):1478-89. PMID: 19817968.
    Citations: 16     Fields:    Translation:AnimalsCells
  122. Simon KC, Chen H, Gao X, Schwarzschild MA, Ascherio A. Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease. Mov Disord. 2009 Jul 15; 24(9):1359-65. PMID: 19424986.
    Citations: 20     Fields:    Translation:Humans
  123. McFarland NR, Fan Z, Xu K, Schwarzschild MA, Feany MB, Hyman BT, McLean PJ. Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. J Neuropathol Exp Neurol. 2009 May; 68(5):515-24. PMID: 19525899.
    Citations: 47     Fields:    Translation:HumansAnimalsCells
  124. Gao X, Schwarzschild MA, Wang H, Ascherio A. Obesity and restless legs syndrome in men and women. Neurology. 2009 Apr 07; 72(14):1255-61. PMID: 19349606.
    Citations: 57     Fields:    Translation:Humans
  125. O'Reilly EJ, Chen H, Gardener H, Gao X, Schwarzschild MA, Ascherio A. Smoking and Parkinson's disease: using parental smoking as a proxy to explore causality. Am J Epidemiol. 2009 Mar 15; 169(6):678-82. PMID: 19131566.
    Citations: 22     Fields:    Translation:Humans
  126. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Genetic determinants of hair color and Parkinson's disease risk. Ann Neurol. 2009 Jan; 65(1):76-82. PMID: 19194882.
    Citations: 45     Fields:    Translation:Humans
  127. Petzer JP, Castagnoli N, Schwarzschild MA, Chen JF, Van der Schyf CJ. Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease. Neurotherapeutics. 2009 Jan; 6(1):141-51. PMID: 19110205.
    Citations: 12     Fields:    Translation:HumansAnimals
  128. Yang JN, Björklund O, Lindström-Törnqvist K, Lindgren E, Eriksson TM, Kahlström J, Chen JF, Schwarzschild MA, Tobler I, Fredholm BB. Mice heterozygous for both A1 and A(2A) adenosine receptor genes show similarities to mice given long-term caffeine. J Appl Physiol (1985). 2009 Feb; 106(2):631-9. PMID: 19036889.
    Citations: 15     Fields:    Translation:AnimalsCells
  129. Irizarry MC, Raman R, Schwarzschild MA, Becerra LM, Thomas RG, Peterson RC, Ascherio A, Aisen PS. Plasma urate and progression of mild cognitive impairment. Neurodegener Dis. 2009; 6(1-2):23-8. PMID: 19066433.
    Citations: 37     Fields:    Translation:Humans
  130. Bronstein J, Carvey P, Chen H, Cory-Slechta D, DiMonte D, Duda J, English P, Goldman S, Grate S, Hansen J, Hoppin J, Jewell S, Kamel F, Koroshetz W, Langston JW, Logroscino G, Nelson L, Ravina B, Rocca W, Ross GW, Schettler T, Schwarzschild M, Scott B, Seegal R, Singleton A, Steenland K, Tanner CM, Van Den Eeden S, Weisskopf M. Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007. Environ Health Perspect. 2009 Jan; 117(1):117-21. PMID: 19165397.
    Citations: 21     Fields:    Translation:Humans
  131. Tikh EI, Fenton RA, Chen JF, Schwarzschild MA, Dobson JG. Adenosine A1 and A2A receptor regulation of protein phosphatase 2A in the murine heart. J Cell Physiol. 2008 Jul; 216(1):83-90. PMID: 18181173.
    Citations: 9     Fields:    Translation:AnimalsCells
  132. Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A, Hyson C, Gorbold E, Rudolph A, Kieburtz K, Fahn S, Gauger L, Goetz C, Seibyl J, Forrest M, Ondrasik J. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008 Jun; 65(6):716-23. PMID: 18413464.
    Citations: 105     Fields:    Translation:Humans
  133. Gao X, Chen H, Schwarzschild MA, Logroscino G, Ascherio A. Perceived imbalance and risk of Parkinson's disease. Mov Disord. 2008 Mar 15; 23(4):613-6. PMID: 18181208.
    Citations: 8     Fields:    Translation:Humans
  134. Gao X, Chen H, Choi HK, Curhan G, Schwarzschild MA, Ascherio A. Diet, urate, and Parkinson's disease risk in men. Am J Epidemiol. 2008 Apr 01; 167(7):831-8. PMID: 18326873.
    Citations: 62     Fields:    Translation:Humans
  135. Wang H, Chen H, Gao X, McGrath M, Deer D, De Vivo I, Schwarzschild MA, Ascherio A. Telomere length and risk of Parkinson's disease. Mov Disord. 2008 Jan 30; 23(2):302-5. PMID: 18044760.
    Citations: 44     Fields:    Translation:HumansCells
  136. Thacker EL, Chen H, Patel AV, McCullough ML, Calle EE, Thun MJ, Schwarzschild MA, Ascherio A. Recreational physical activity and risk of Parkinson's disease. Mov Disord. 2008 Jan; 23(1):69-74. PMID: 17960818.
    Citations: 59     Fields:    Translation:Humans
  137. Schwarzschild MA (guest editor) Zigmond M (editor). "Targeting Adenosine A2A Receptors in Parkinson's Disease and other CNS Disorders". Progress in Neurobiology [journal Special Issue]. 2007; 261-347.
  138. Tebano MT, Martire A, Potenza RL, Grò C, Pepponi R, Armida M, Domenici MR, Schwarzschild MA, Chen JF, Popoli P. Adenosine A(2A) receptors are required for normal BDNF levels and BDNF-induced potentiation of synaptic transmission in the mouse hippocampus. J Neurochem. 2008 Jan; 104(1):279-86. PMID: 18005343.
    Citations: 30     Fields:    Translation:AnimalsCells
  139. Gao X, Chen H, Fung TT, Logroscino G, Schwarzschild MA, Hu FB, Ascherio A. Prospective study of dietary pattern and risk of Parkinson disease. Am J Clin Nutr. 2007 Nov; 86(5):1486-94. PMID: 17991663.
    Citations: 70     Fields:    Translation:Humans
  140. Schwarzschild MA. Adenosine A2A antagonists as neurotherapeutics: crossing the bridge. Prog Neurobiol. 2007 Dec; 83(5):261-2. PMID: 17997007.
    Citations: 8     Fields:    Translation:HumansAnimals
  141. Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol. 2008 Jan 01; 167(1):90-5. PMID: 17890755.
    Citations: 102     Fields:    Translation:Humans
  142. Gao X, Chen H, Schwarzschild MA, Glasser DB, Logroscino G, Rimm EB, Ascherio A. Erectile function and risk of Parkinson's disease. Am J Epidemiol. 2007 Dec 15; 166(12):1446-50. PMID: 17875583.
    Citations: 24     Fields:    Translation:Humans